search
Back to results

Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Primary Purpose

Brain and Central Nervous System Tumors

Status
Completed
Phase
Phase 2
Locations
Switzerland
Study Type
Interventional
Intervention
sagopilone
fluorescence in situ hybridization
gene expression analysis
immunohistochemistry staining method
laboratory biomarker analysis
pharmacological study
Sponsored by
European Organisation for Research and Treatment of Cancer - EORTC
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring adult glioblastoma, recurrent adult brain tumor, adult giant cell glioblastoma, adult gliosarcoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Histologically confirmed glioblastoma

    • Presence of oligodendroglial elements allowed provided they make up < 25% of tumor
  • Measurable disease, defined as ≥ 1 bidimensionally measurable target lesion with a largest diameter of ≥ 2 cm by MRI within the past 2 weeks
  • Recurrent disease

    • Documented by MRI after failing prior therapy (usually standard radiotherapy with concurrent and maintenance temozolomide)
    • Subsequent histologic confirmation of recurrence required for patients who received prior high-dose radiotherapy (> 65 Gy), stereotactic radiosurgery, or internal radiotherapy
  • Multifocal disease that is not amenable to radiotherapy allowed provided the patient received no more than 1 line of prior chemotherapy

PATIENT CHARACTERISTICS:

  • WHO performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • AST and ALT < 2.5 times ULN
  • Alkaline phosphatase < 2.5 times ULN
  • Creatinine < 1.5 times ULN
  • Clinically normal cardiac function
  • No ischemic heart disease within the past 12 months

    • Stable ischemic heart disease (e.g., treated angina that is stable under appropriate therapy) allowed
  • No New York Heart Association class III or IV cardiac insufficiency
  • No unstable angina
  • No arrhythmia
  • No psychological, familial, sociological, or geographical factors that would preclude study compliance
  • No other malignancy except cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile female patients must use effective contraception during and for 3 months after completion of study treatment
  • Fertile male patients must use effective contraception during and for 6 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
  • More than 3 months since prior radiotherapy to the brain
  • More than 3 months since prior surgery for recurrent primary brain tumor unless 1 of the following criteria are met:

    • Measurable residual disease documented by immediate (within 72 hours) postoperative imaging
    • Evidence of a progressive and measurable target lesion found at postoperative follow-up
    • Presence of a second measurable target lesion outside the surgical area
  • Prior adjuvant temozolomide as first-line therapy allowed
  • No prior chemotherapy for recurrent glioblastoma

    • One prior chemotherapy regimen given as adjuvant therapy allowed
  • Concurrent corticosteroids allowed provided dose is stable or decreasing for ≥ 1 week
  • No concurrent phenytoin, carbamazepine, or phenobarbital
  • No concurrent Hypericum perforatum (St. John's wort)
  • No concurrent enzyme-inducing antiepileptic drugs (EIAEDs)

    • Patients on EIAEDs should have been switched to non-EIAEDs with a wash-out period of ≥ 1 month
  • No other concurrent anticancer agents (except alternative or homeopathic medicine)
  • No other concurrent investigational treatment

Sites / Locations

  • Centre Hospitalier Universitaire Vaudois

Outcomes

Primary Outcome Measures

Treatment success (complete or partial response or a progression-free survival at 6 months)

Secondary Outcome Measures

Objective response
Duration of response
Toxicity
Progression-free survival at 6 months
Overall survival at 6 and 12 months

Full Information

First Posted
January 16, 2007
Last Updated
September 20, 2012
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
search

1. Study Identification

Unique Protocol Identification Number
NCT00424060
Brief Title
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
Official Title
Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
December 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Organisation for Research and Treatment of Cancer - EORTC

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone ZK-219477 works in treating patients with recurrent glioblastoma.
Detailed Description
OBJECTIVES: Primary Assess the therapeutic activity of epothilone ZK-219477 in patients with recurrent glioblastoma. Secondary Determine the safety profile, mechanism of action, and pharmacokinetics of this drug in these patients. Gather information about the biological characteristics of the patients' tumor that may provide information on response or resistance to this drug. OUTLINE: This is a nonrandomized, open-label, multicenter study. Patients receive epothilone ZK-219477 IV over 3 hours on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline for biomarker analysis and for comparison of genetic alterations in tumor tissue with germline DNA. Blood samples are also collected periodically during course 1 for pharmacokinetic studies. Tumor tissue obtained at diagnosis, and possibly recurrence, is used for immunohistochemical analyses for biomarkers. Fluorescent in situ hybridization (FISH) is used to detect genetic alterations and gene expression. After completion of study treatment, patients are followed every 3 months. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain and Central Nervous System Tumors
Keywords
adult glioblastoma, recurrent adult brain tumor, adult giant cell glioblastoma, adult gliosarcoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
38 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
sagopilone
Intervention Type
Genetic
Intervention Name(s)
fluorescence in situ hybridization
Intervention Type
Genetic
Intervention Name(s)
gene expression analysis
Intervention Type
Other
Intervention Name(s)
immunohistochemistry staining method
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Type
Other
Intervention Name(s)
pharmacological study
Primary Outcome Measure Information:
Title
Treatment success (complete or partial response or a progression-free survival at 6 months)
Secondary Outcome Measure Information:
Title
Objective response
Title
Duration of response
Title
Toxicity
Title
Progression-free survival at 6 months
Title
Overall survival at 6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed glioblastoma Presence of oligodendroglial elements allowed provided they make up < 25% of tumor Measurable disease, defined as ≥ 1 bidimensionally measurable target lesion with a largest diameter of ≥ 2 cm by MRI within the past 2 weeks Recurrent disease Documented by MRI after failing prior therapy (usually standard radiotherapy with concurrent and maintenance temozolomide) Subsequent histologic confirmation of recurrence required for patients who received prior high-dose radiotherapy (> 65 Gy), stereotactic radiosurgery, or internal radiotherapy Multifocal disease that is not amenable to radiotherapy allowed provided the patient received no more than 1 line of prior chemotherapy PATIENT CHARACTERISTICS: WHO performance status 0-2 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin < 1.5 times upper limit of normal (ULN) AST and ALT < 2.5 times ULN Alkaline phosphatase < 2.5 times ULN Creatinine < 1.5 times ULN Clinically normal cardiac function No ischemic heart disease within the past 12 months Stable ischemic heart disease (e.g., treated angina that is stable under appropriate therapy) allowed No New York Heart Association class III or IV cardiac insufficiency No unstable angina No arrhythmia No psychological, familial, sociological, or geographical factors that would preclude study compliance No other malignancy except cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile female patients must use effective contraception during and for 3 months after completion of study treatment Fertile male patients must use effective contraception during and for 6 months after completion of study treatment PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) More than 3 months since prior radiotherapy to the brain More than 3 months since prior surgery for recurrent primary brain tumor unless 1 of the following criteria are met: Measurable residual disease documented by immediate (within 72 hours) postoperative imaging Evidence of a progressive and measurable target lesion found at postoperative follow-up Presence of a second measurable target lesion outside the surgical area Prior adjuvant temozolomide as first-line therapy allowed No prior chemotherapy for recurrent glioblastoma One prior chemotherapy regimen given as adjuvant therapy allowed Concurrent corticosteroids allowed provided dose is stable or decreasing for ≥ 1 week No concurrent phenytoin, carbamazepine, or phenobarbital No concurrent Hypericum perforatum (St. John's wort) No concurrent enzyme-inducing antiepileptic drugs (EIAEDs) Patients on EIAEDs should have been switched to non-EIAEDs with a wash-out period of ≥ 1 month No other concurrent anticancer agents (except alternative or homeopathic medicine) No other concurrent investigational treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roger Stupp, MD
Organizational Affiliation
Centre Hospitalier Universitaire Vaudois
Official's Role
Study Chair
Facility Information:
Facility Name
Centre Hospitalier Universitaire Vaudois
City
Lausanne
ZIP/Postal Code
CH-1011
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
21321091
Citation
Stupp R, Tosoni A, Bromberg JEC, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol. 2011 Sep;22(9):2144-2149. doi: 10.1093/annonc/mdq729. Epub 2011 Feb 14.
Results Reference
result
Citation
Stupp R, Tosoni W, Taal W, et al.: Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: initial report of the EORTC study 26061. [Abstract] J Clin Oncol 26 (Suppl 15): A-2015, 2008.
Results Reference
result

Learn more about this trial

Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

We'll reach out to this number within 24 hrs